MedTrace Logo

Zilver® PTX® V Clinical Study

NCT01901289 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-03-02

Study results available
· View outcomes & findings →

Summary

The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.

Conditions

  • Peripheral Arterial Disease

Interventions

DEVICE

Zilver® PTX® Drug-Eluting Peripheral Stent

Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.

Sponsors & Collaborators

  • Cook Research Incorporated

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-11-18
Completion
2021-02-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01901289 on ClinicalTrials.gov